Stock Price Quote

SHREE YAAX PHARMA & COSMETICS LTD.

NSE : NABSE : 531482ISIN CODE : INE325F01012Industry : Pharmaceuticals & DrugsHouse : Private
BSE1.580 (0 %)
PREV CLOSE ( ) 1.58
OPEN PRICE ( ) 1.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2499
TODAY'S LOW / HIGH ( )1.58 1.60
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1995
Management Info
- Chairman - Managing Director
Registered Office

Address Vaghela Avenue, 4Th Floor, Near Havmor Restaurant Navrangpura,
Ahmedabad,
Gujarat-380009

Phone 079- 6568306 6569689

Email --

Website NA

Registrars Details
Purva Shareregistry (India) Pvt Ltd
33 Printing House , 28 D Police Court Lane,Behind Old Handloom House,Fort,Mumbai
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR Dec 04 ANNUAL 05
Net Profit25.78
Gross Profit 25.78
Operating Profit 26.29
Net Sales 148.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

No Data Found

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.